Evidence map›Paper›PMID 39251168›Full record

ReviewGastroenterology2025

Portal Fibrosis and the Ductular Reaction: Pathophysiological Role in the Progression of Liver Disease and Translational Opportunities.

Vikas Gupta, Tejasav S Sehrawat, Massimo Pinzani, Mario Strazzabosco

Abstract readReview
In one paragraph

Review in Gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Ductular Reaction Underlies Development of Portal Hypertension in Biliary Atresia.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
  2. Melatonin Alleviates Graft Biliary Fibrosis by Inhibiting VIMAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  3. The hepatic portal area in homeostasis and disease.Clinical and molecular hepatology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Vikas GuptaLiver Center and Section of Digestive Diseases, Department of Internal Medicine, Yale University, New Haven, Connecticut.
Tejasav S SehrawatLiver Center and Section of Digestive Diseases, Department of Internal Medicine, Yale University, New Haven, Connecticut.
Massimo PinzaniUCL Institute for Liver & Digestive Health, Royal Free Hospital, London, United Kingdom; University of Pittsburgh Medical Center-Mediterranean Institute for Transplantation and Highly Specialized Therapies, Palermo, Italy.
Mario StrazzaboscoLiver Center and Section of Digestive Diseases, Department of Internal Medicine, Yale University, New Haven, Connecticut. Electronic address: mario.strazzabosco@yale.edu.

Funding

Yale Liver CenterP30DK034989 · NIDDK · YALE UNIVERSITY · PI YASUKO IWAKIRI · 1986 to 2026
$31.1M
Liver disease in CF: CFTR controls innate immunity in biliary epitheliumR01DK096096 · NIDDK · YALE UNIVERSITY · PI STRAZZABOSCO, MARIO · 2013 to 2022
$4.6M
Cross talk between epithelial, inflammatory and mesenchymal cells in the development of portal fibrosisR01DK101528 · NIDDK · YALE UNIVERSITY · PI STRAZZABOSCO, MARIO · 2015 to 2023
$3.5M
NIDDK NIH HHS P30 DK034989NIDDK NIH HHS R01 DK096096NIDDK NIH HHS R01 DK101528
6 · The paper itself

Abstract

A consistent feature of chronic liver diseases and the hallmark of pathologic repair is the so-called "ductular reaction." This is a histologic abnormality characterized by an expansion of dysmorphic cholangiocytes inside and around portal spaces infiltrated by inflammatory, mesenchymal, and vascular cells. The ductular reaction is a highly regulated response based on the reactivation of morphogenetic signaling mechanisms and a complex crosstalk among a multitude of cell types. The nature and mechanism of these exchanges determine the difference between healthy regenerative liver repair and pathologic repair. An orchestrated signaling among cell types directs mesenchymal cells to deposit a specific extracellular matrix with distinct physical and biochemical properties defined as portal fibrosis. Progression of fibrosis leads to vast architectural and vascular changes known as "liver cirrhosis." The signals regulating the ecology of this microenvironment are just beginning to be addressed. Contrary to the tumor microenvironment, immune modulation inside this "benign" microenvironment is scarcely known. One of the reasons for this is that both the ductular reaction and portal fibrosis have been primarily considered a manifestation of cholestatic liver disease, whereas this phenomenon is also present, albeit with distinctive features, in all chronic human liver diseases. Novel human-derived cellular models and progress in "omics" technologies are increasing our knowledge at a fast pace. Most importantly, this knowledge is on the edge of generating new diagnostic and therapeutic advances. Here, we will critically review the latest advances, in terms of mechanisms, pathophysiology, and treatment prospects. In addition, we will delineate future avenues of research, including innovative translational opportunities.

Indexed as

LiverLiver CirrhosisLiver DiseasesAnimalsDisease ProgressionHumansSignal TransductionTranslational Research, BiomedicalAlcoholic HepatitisALDCholangiopathyCirrhosisMASHMetabolic Dysfunction–Associated Steatotic Liver Disease

Identifiers

PMID39251168
PMCPMC11885590

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.